Research programme: 5-lipooxygenase inhibitors - Qurient TherapeuticsAlternative Names: 5-LO inhibitors - Qurient Therapeutics
Latest Information Update: 14 Sep 2016
At a glance
- Originator Qurient Co
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Asthma
Most Recent Events
- 14 Sep 2016 Early research in Asthma in South Korea (unspecified route) before September 2016